Jia Liu – CEO, DreamCIS, South Korea
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
Address: 1010, 10F, Jeokseon Hyundai Bld, 80, Jeokseon-dong, Seoul, Jongno-gu, Seoul,Republic of Korea
Tel: +82 2 2010 4500
DreamCIS is a full service contract research organization (CRO) that offers to the pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. DreamCIS provides clinical trial services for a broad and detailed range of therapeutic area in accordance with the standard operating procedures consistent with both Republic of Korean regulations and global standards including ICH-GCP guidelines. DreamCIS aims at enhancing both the reliability of its clinical services provided and product competitiveness by striving to maintain the consistency in quality of its services. Accomplishing this goal will no doubt enable us to contribute to the health of the people. DreamCIS has its Specialist Advisory Committee comprised of high-level specialists in their field to provide comprehensive and specialized clinical services. The community in partnership with DreamCIS include Ionet Republic of Korea which was organized by DreamCIS exclusively for the development of Web-CRF program, DreamCIS’s patented product, Yonsei University Department of Biostatics Medical College, YOU & ME Patent and Law Firm, Yonsei University Research Institute of Food & Nutrition, SMSI (Seoul Medical Science Institute), Biotoxtech Co.,Ltd. DreamCIS has launched a business partnership with Gleneagles CRC (Singapore), a leading CRO/SMO in the Asia Pacific region, with the aim to conduct multi-national clinical trials seamlessly for multi-national customers as well. Founded in April, 2000, DreamCIS has ever since been dedicated to providing a full range of clinical services for a number of customers/sponsors, including major pharmaceutical companies, multi-national pharmaceutical companies, bio venture companies, health food producers, and medical device manufacturers in Republic of Korea. DreamCIS will continue striving to provide customers reliable clinical trial data while conducting all of clinical trials using our expertise and significant experience in the field of clinical trials.
It aims to provide customers differentiated services based on strict quality control in a scientific and systematic manner and high ethical standards. DreamCIS’ key service areas include: ㆍClinical trials for medicines / medical devices ㆍPost-marketing surveillance (PMS) ㆍQA audit ㆍData management and Statistical analysis ㆍHealth functional foods Trials ㆍPre-clinical trials management ㆍTraining and dispatch of clinical research nurses
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion…
Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their…
Industry players – from Big Pharma giants to small local startups – are bringing new, innovative solutions to market in Korea in order to try and solve the country’s diabetes…
The nation of South Korea has overtaken many of its regional counterparts to boast a highly impressive biosimilars pipeline. Here, key stakeholders in Korean biologics and biosimilars explain how. …
ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its parent company’s…
CEO of the Life Science division of LG – one of Korea most recognized global brands – Dr Jeewoong Son has spent much of his career gathering the knowhow to…
One of the indisputable economic success stories of the last half-century, South Korea now stands as the world’s 11th largest economy, with a reputation for industrial excellence and innovation. As…
The Korean cosmetics market is now the 8th largest in the world, with 2.9 percent of the global market share, capitalising on the global rise in interest for Korean culture,…
SK Plasma is a blood plasma company that was spun off from SK Chemicals in 2015. Its CEO, Yun Ho Kim, offers his insights into the company’s vision to establish…
French-headquartered logistics and distribution provider Bolloré Logistics has been steadily increasing its footprint in Korean life sciences in recent years – attaining international certifications to assure potential partners of their…
Rene Wipperich took the helm of Galderma’s Korean affiliate in August 2018. He breaks down the performance of the affiliate across its four business segments and the main competitive advantages…
YD Global Life Science is a Korean biopharmaceutical company with ambitions to become a global leader in new drug development with USD 1 billion in revenues. Its founder & CEO,…
See our Cookie Privacy Policy Here
